Skip to main content
OpenTrials
Completed

NCT Number: NCT01113424

Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum

Bioequivalence between oral nicotine replacement products and Nicorette® gum.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Berzelius Clinical Research Center

Linköping, SE-582 25, Sweden

About this study

This study compares a new oral Nicotine Replacement Therapy (NRT) product containing 2 and 4 mg nicotine with Nicorette® gum 2 mg and 4 mg, after 12 hours of nicotine abstinence, with respect to nicotine pharmacokinetics, during 10 hours after start of administration. Single doses of each treatment are given once in the morning during four separate treatment visits scheduled in a crossover setting with randomized treatment sequences. The study will include 88 healthy smokers between 18-50 years, who have been smoking at least 10 cigarettes daily during at least one year preceding inclusion. Subjects and study personnel will be aware of which treatment is administered at a given visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy smokers, smoking at least 10 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
  • Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
  • A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion criteria

  • Pregnancy, lactation or intended pregnancy.
  • Treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.

Treatment and study plan

nicotine

Drug

Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg

Other names: Not yet marketed

Nicorette® (Nicotine Gum)

Drug

Single-dose of marketed nicotine gum 2 mg or 4 mg

Other names: Nicorette®

Primary outcomes

  1. Pharmacokinetic measurements

    Time frame: Baseline and during 10 hours after product administration

    Pharmacokinetic measurements including:

    • the maximum observed nicotine concentration in plasma (Cmax)
    • the area under the plasma concentration-vs.-time curve until the last measurable concentration (AUCt)
    • the area under the plasma concentration-vs.-time curve until infinity (AUCinf)

Secondary outcomes

  1. Tmax

    Time frame: during 10 hours after start of product administration

    The time of occurrence of Cmax (tmax) following product administration

  2. λz

    Time frame: during 10 hours after start of product administration

    The terminal nicotine elimination rate constant (λz)

  3. Residual Nicotine

    Time frame: After 30 minutes of chewing

    The amount of nicotine released from Nicorette® gum 2 and 4 mg during 30 minutes' chewing.

  4. Dissolution Time

    Time frame: From product administration until completely dissolved

    Actual time required for oral dissolution of new NRT products following product administration

Sponsors and collaborators

Lead sponsor

McNeil AB

Industry

Registry information

Official study title

Bioequivalence Between Oral Nicotine Replacement Products and Nicorette® Gum - A Study in Healthy Smokers

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
Apr 29, 2010
Registry last updated
Jul 10, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.